<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37238732</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2218-273X</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>19</Day></PubDate></JournalIssue><Title>Biomolecules</Title><ISOAbbreviation>Biomolecules</ISOAbbreviation></Journal><ArticleTitle>Evidence of Metabolic Dysfunction in Amyotrophic Lateral Sclerosis (ALS) Patients and Animal Models.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">863</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biom13050863</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that affects motor neurons, leading to muscle weakness, paralysis, and eventual death. Research from the past few decades has appreciated that ALS is not only a disease of the motor neurons but also a disease that involves systemic metabolic dysfunction. This review will examine the foundational research of understanding metabolic dysfunction in ALS and provide an overview of past and current studies in ALS patients and animal models, spanning from full systems to various metabolic organs. While ALS-affected muscle tissue exhibits elevated energy demand and a fuel preference switch from glycolysis to fatty acid oxidation, adipose tissue in ALS undergoes increased lipolysis. Dysfunctions in the liver and pancreas contribute to impaired glucose homeostasis and insulin secretion. The central nervous system (CNS) displays abnormal glucose regulation, mitochondrial dysfunction, and increased oxidative stress. Importantly, the hypothalamus, a brain region that controls whole-body metabolism, undergoes atrophy associated with pathological aggregates of TDP-43. This review will also cover past and present treatment options that target metabolic dysfunction in ALS and provide insights into the future of metabolism research in ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Maksimovic</LastName><ForeName>Katarina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, ON M5G 0A4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Youssef</LastName><ForeName>Mohieldin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, ON M5G 0A4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Justin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, ON M5G 0A4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sung</LastName><ForeName>Hoon-Ki</ForeName><Initials>HK</Initials><Identifier Source="ORCID">0000-0001-6677-9385</Identifier><AffiliationInfo><Affiliation>Translational Medicine Program, The Hospital for Sick Children, Toronto, ON M5G 0A4, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine &amp; Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jeehye</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, ON M5G 0A4, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomolecules</MedlineTA><NlmUniqueID>101596414</NlmUniqueID><ISSNLinking>2218-273X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D023421" MajorTopicYN="N">Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">hypermetabolism</Keyword><Keyword MajorTopicYN="N">metabolic dysfunction</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>27</Day><Hour>9</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>27</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37238732</ArticleId><ArticleId IdType="pmc">PMC10216611</ArticleId><ArticleId IdType="doi">10.3390/biom13050863</ArticleId><ArticleId IdType="pii">biom13050863</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kumar D.R., Aslinia F., Yale S.H., Mazza J.J. Jean-Martin Charcot: The Father of Neurology. Clin. Med. Res. 2011;9:46&#x2013;49. doi: 10.3121/cmr.2009.883.</Citation><ArticleIdList><ArticleId IdType="doi">10.3121/cmr.2009.883</ArticleId><ArticleId IdType="pmc">PMC3064755</ArticleId><ArticleId IdType="pubmed">20739583</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan M.C., Vucic S., Cheah B.C., Turner M.R., Eisen A., Hardiman O., Burrell J.R., Zoing M.C. Amyotrophic Lateral Sclerosis. Lancet. 2011;377:942&#x2013;955. doi: 10.1016/S0140-6736(10)61156-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor J.P., Brown R.H., Jr., Cleveland D.W. Decoding ALS: From Genes to Mechanism. Nature. 2016;539:197&#x2013;206. doi: 10.1038/nature20413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R., Flynn L.L., Pitout I.L., Fletcher S., Wilton S.D., Akkari P.A. ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? Front. Neurosci. 2019;13:1310. doi: 10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Fayemendy P., Marin B., Labrunie A., Boirie Y., Walrand S., Achamrah N., Co&#xeb;ffier M., Preux P.-M., Lautrette G., Desport J.-C., et al. Hypermetabolism Is a Reality in Amyotrophic Lateral Sclerosis Compared to Healthy Subjects. J. Neurol. Sci. 2021;420:117257. doi: 10.1016/j.jns.2020.117257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2020.117257</ArticleId><ArticleId IdType="pubmed">33290920</ArticleId></ArticleIdList></Reference><Reference><Citation>Desport J.C., Preux P.M., Magy L., Boirie Y., Vallat J.M., Beaufr&#xe8;re B., Couratier P. Factors Correlated with Hypermetabolism in Patients with Amyotrophic Lateral Sclerosis. Am. J. Clin. Nutr. 2001;74:328&#x2013;334. doi: 10.1093/ajcn/74.3.328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcn/74.3.328</ArticleId><ArticleId IdType="pubmed">11522556</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L., Pradat P.F., Ludolph A.C., Loeffler J.P. Energy Metabolism in Amyotrophic Lateral Sclerosis. Lancet Neurol. 2011;10:75&#x2013;82. doi: 10.1016/S1474-4422(10)70224-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70224-6</ArticleId><ArticleId IdType="pubmed">21035400</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcuzzo S., Zucca I., Mastropietro A., de Rosbo N.K., Cavalcante P., Tartari S., Bonanno S., Preite L., Mantegazza R., Bernasconi P. Hind Limb Muscle Atrophy Precedes Cerebral Neuronal Degeneration in G93A-SOD1 Mouse Model of Amyotrophic Lateral Sclerosis: A Longitudinal MRI Study. Exp. Neurol. 2011;231:30&#x2013;37. doi: 10.1016/j.expneurol.2011.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2011.05.007</ArticleId><ArticleId IdType="pubmed">21620832</ArticleId></ArticleIdList></Reference><Reference><Citation>Peter R.S., Rosenbohm A., Dupuis L., Brehme T., Kassubek J., Rothenbacher D., Nagel G., Ludolph A.C. Life Course Body Mass Index and Risk and Prognosis of Amyotrophic Lateral Sclerosis: Results from the ALS Registry Swabia. Eur. J. Epidemiol. 2017;32:901&#x2013;908. doi: 10.1007/s10654-017-0318-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-017-0318-z</ArticleId><ArticleId IdType="pubmed">28975435</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawaid A., Murthy S.B., Wilson A.M., Qureshi S.U., Amro M.J., Wheaton M., Simpson E., Harati Y., Strutt A.M., York M.K., et al. A Decrease in Body Mass Index Is Associated with Faster Progression of Motor Symptoms and Shorter Survival in ALS. Amyotroph. Lateral Scler. 2010;11:542&#x2013;548. doi: 10.3109/17482968.2010.482592.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.482592</ArticleId><ArticleId IdType="pubmed">20500116</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakayama Y., Shimizu T., Matsuda C., Haraguchi M., Hayashi K., Bokuda K., Nagao M., Kawata A., Ishikawa-Takata K., Isozaki E. Body Weight Variation Predicts Disease Progression after Invasive Ventilation in Amyotrophic Lateral Sclerosis. Sci. Rep. 2019;9:12262. doi: 10.1038/s41598-019-48831-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-48831-9</ArticleId><ArticleId IdType="pmc">PMC6706382</ArticleId><ArticleId IdType="pubmed">31439899</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf J., Safer A., W&#xf6;hrle J.C., Palm F., Nix W.A., Maschke M., Grau A.J. Factors Predicting One-Year Mortality in Amyotrophic Lateral Sclerosis Patients&#x2014;Data from a Population-Based Registry. BMC Neurol. 2014;14:197. doi: 10.1186/s12883-014-0197-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-014-0197-9</ArticleId><ArticleId IdType="pmc">PMC4189670</ArticleId><ArticleId IdType="pubmed">25280575</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakken O., Meyer H.E., Stigum H., Holm&#xf8;y T. High BMI Is Associated with Low ALS Risk: A Population-Based Study. Neurology. 2019;93:e424&#x2013;e432. doi: 10.1212/WNL.0000000000007861.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007861</ArticleId><ArticleId IdType="pubmed">31243073</ArticleId></ArticleIdList></Reference><Reference><Citation>Desport J.C., Preux P.M., Truong C.T., Courat L., Vallat J.M., Couratier P. Nutritional Assessment and Survival in ALS Patients. Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 2000;1:91&#x2013;96. doi: 10.1080/14660820050515386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820050515386</ArticleId><ArticleId IdType="pubmed">11467055</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm T., Maier A., Wicks P., Lang D., Linke P., M&#xfc;nch C., Steinfurth L., Meyer R., Meyer T. Severe Loss of Appetite in Amyotrophic Lateral Sclerosis Patients: Online Self-Assessment Study. Interact. J. Med. Res. 2013;2:e8. doi: 10.2196/ijmr.2463.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/ijmr.2463</ArticleId><ArticleId IdType="pmc">PMC3632382</ArticleId><ArticleId IdType="pubmed">23608722</ArticleId></ArticleIdList></Reference><Reference><Citation>Desport J.C., Preux P.M., Truong T.C., Vallat J.M., Sautereau D., Couratier P. Nutritional Status Is a Prognostic Factor for Survival in ALS Patients. Neurology. 1999;53:1059&#x2013;1063. doi: 10.1212/WNL.53.5.1059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.53.5.1059</ArticleId><ArticleId IdType="pubmed">10496266</ArticleId></ArticleIdList></Reference><Reference><Citation>Onesti E., Schettino I., Gori M.C., Frasca V., Ceccanti M., Cambieri C., Ruoppolo G., Inghilleri M. Dysphagia in Amyotrophic Lateral Sclerosis: Impact on Patient Behavior, Diet Adaptation, and Riluzole Management. Front. Neurol. 2017;8:94. doi: 10.3389/fneur.2017.00094.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2017.00094</ArticleId><ArticleId IdType="pmc">PMC5359548</ArticleId><ArticleId IdType="pubmed">28377742</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouteloup C., Desport J.-C., Clavelou P., Guy N., Derumeaux-Burel H., Ferrier A., Couratier P. Hypermetabolism in ALS Patients: An Early and Persistent Phenomenon. J. Neurol. 2009;256:1236&#x2013;1242. doi: 10.1007/s00415-009-5100-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-009-5100-z</ArticleId><ArticleId IdType="pubmed">19306035</ArticleId></ArticleIdList></Reference><Reference><Citation>Poehlman E.T. A Review: Exercise and Its Influence on Resting Energy Metabolism in Man. Med. Sci. Sport. Exerc. 1989;21:515. doi: 10.1249/00005768-198910000-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1249/00005768-198910000-00005</ArticleId><ArticleId IdType="pubmed">2691813</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyn F.J., Ioannides Z.A., van Eijk R.P., Heggie S., Thorpe K.A., Ceslis A., Heshmat S., Henders A.K., Wray N.R., van den Berg L.H., et al. Hypermetabolism in ALS Is Associated with Greater Functional Decline and Shorter Survival. J. Neurol. Neurosurg. Psychiatry. 2018;89:1016&#x2013;1023. doi: 10.1136/jnnp-2017-317887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317887</ArticleId><ArticleId IdType="pmc">PMC6166607</ArticleId><ArticleId IdType="pubmed">29706605</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaisman N., Lusaus M., Nefussy B., Niv E., Comaneshter D., Hallack R., Drory V.E. Do Patients with Amyotrophic Lateral Sclerosis (ALS) Have Increased Energy Needs? J. Neurol. Sci. 2009;279:26&#x2013;29. doi: 10.1016/j.jns.2008.12.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2008.12.027</ArticleId><ArticleId IdType="pubmed">19185883</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S., Deng J., Jaffa M., Cudkowicz M.E., Wills A.-M. Body Mass Index, Not Dyslipidemia, Is an Independent Predictor of Survival in Amyotrophic Lateral Sclerosis. Muscle Nerve. 2011;44:20&#x2013;24. doi: 10.1002/mus.22114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.22114</ArticleId><ArticleId IdType="pmc">PMC4441750</ArticleId><ArticleId IdType="pubmed">21607987</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao C.S., van Bruggen R., Kim J.R., Chen X.X.L., Chan C., Lee J., Cho W.I., Zhao M., Arndt C., Maksimovic K., et al. Selective Neuronal Degeneration in MATR3 S85C Knock-in Mouse Model of Early-Stage ALS. Nat. Commun. 2020;11:5304. doi: 10.1038/s41467-020-18949-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-18949-w</ArticleId><ArticleId IdType="pmc">PMC7576598</ArticleId><ArticleId IdType="pubmed">33082323</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell J.C., McGoldrick P., Vance C., Hortobagyi T., Sreedharan J., Rogelj B., Tudor E.L., Smith B.N., Klasen C., Miller C.C., et al. Overexpression of Human Wild-Type FUS Causes Progressive Motor Neuron Degeneration in an Age- and Dose-Dependent Fashion. Acta Neuropathol. 2013;125:273&#x2013;288. doi: 10.1007/s00401-012-1043-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-1043-z</ArticleId><ArticleId IdType="pmc">PMC3549237</ArticleId><ArticleId IdType="pubmed">22961620</ArticleId></ArticleIdList></Reference><Reference><Citation>Sephton C.F., Tang A.A., Kulkarni A., West J., Brooks M., Stubblefield J.J., Liu Y., Zhang M.Q., Green C.B., Huber K.M., et al. Activity-Dependent FUS Dysregulation Disrupts Synaptic Homeostasis. Proc. Natl. Acad. Sci. USA. 2014;111:E4769&#x2013;E4778. doi: 10.1073/pnas.1406162111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1406162111</ArticleId><ArticleId IdType="pmc">PMC4226112</ArticleId><ArticleId IdType="pubmed">25324524</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson H.K., Deykin A.V., Bronovitsky E.V., Ovchinnikov R.K., Ustyugov A.A., Shelkovnikova T.A., Kukharsky M.S., Ermolkevich T.G., Goldman I.L., Sadchikova E.R., et al. Early Lethality and Neuronal Proteinopathy in Mice Expressing Cytoplasm-Targeted FUS That Lacks the RNA Recognition Motif. Amyotroph. Lateral Scler. Front. Degener. 2015;16:402&#x2013;409. doi: 10.3109/21678421.2015.1040994.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1040994</ArticleId><ArticleId IdType="pmc">PMC4811325</ArticleId><ArticleId IdType="pubmed">25991062</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew J., Gendron T.F., Prudencio M., Sasaguri H., Zhang Y.-J., Castanedes-Casey M., Lee C.W., Jansen-West K., Kurti A., Murray M.E., et al. C9ORF72 Repeat Expansions in Mice Cause TDP-43 Pathology, Neuronal Loss, and Behavioral Deficits. Science. 2015;348:1151&#x2013;1154. doi: 10.1126/science.aaa9344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa9344</ArticleId><ArticleId IdType="pmc">PMC4692360</ArticleId><ArticleId IdType="pubmed">25977373</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Pattamatta A., Zu T., Reid T., Bardhi O., Borchelt D.R., Yachnis A.T., Ranum L.P.W. C9orf72 BAC Mouse Model with Motor Deficits and Neurodegenerative Features of ALS/FTD. Neuron. 2016;90:521&#x2013;534. doi: 10.1016/j.neuron.2016.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.04.005</ArticleId><ArticleId IdType="pubmed">27112499</ArticleId></ArticleIdList></Reference><Reference><Citation>Stallings N.R., Puttaparthi K., Luther C.M., Burns D.K., Elliott J.L. Progressive Motor Weakness in Transgenic Mice Expressing Human TDP-43. Neurobiol. Dis. 2010;40:404&#x2013;414. doi: 10.1016/j.nbd.2010.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2010.06.017</ArticleId><ArticleId IdType="pubmed">20621187</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannon A., Yang B., Knight J., Farnham I.M., Zhang Y., Wuertzer C.A., D&#x2019;Alton S., Lin W., Castanedes-Casey M., Rousseau L., et al. Neuronal Sensitivity to TDP-43 Overexpression Is Dependent on Timing of Induction. Acta Neuropathol. 2012;123:807&#x2013;823. doi: 10.1007/s00401-012-0979-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-0979-3</ArticleId><ArticleId IdType="pmc">PMC3359456</ArticleId><ArticleId IdType="pubmed">22539017</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y.-F., Gendron T.F., Zhang Y.-J., Lin W.-L., D&#x2019;Alton S., Sheng H., Casey M.C., Tong J., Knight J., Yu X., et al. Wild-Type Human TDP-43 Expression Causes TDP-43 Phosphorylation, Mitochondrial Aggregation, Motor Deficits, and Early Mortality in Transgenic Mice. J. Neurosci. 2010;30:10851&#x2013;10859. doi: 10.1523/JNEUROSCI.1630-10.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1630-10.2010</ArticleId><ArticleId IdType="pmc">PMC3056148</ArticleId><ArticleId IdType="pubmed">20702714</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C., Qiao T., Yu J., Wang H., Guo Y., Salameh J., Metterville J., Parsi S., Yusuf I., Brown R.H., et al. Low-Level Overexpression of Wild Type TDP-43 Causes Late-Onset, Progressive Neurodegeneration and Paralysis in Mice. PLoS ONE. 2022;17:e0255710. doi: 10.1371/journal.pone.0255710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0255710</ArticleId><ArticleId IdType="pmc">PMC8812852</ArticleId><ArticleId IdType="pubmed">35113871</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssens J., Wils H., Kleinberger G., Joris G., Cuijt I., Ceuterick-de Groote C., Van Broeckhoven C., Kumar-Singh S. Overexpression of ALS-Associated p.M337V Human TDP-43 in Mice Worsens Disease Features Compared to Wild-Type Human TDP-43 Mice. Mol. Neurobiol. 2013;48:22&#x2013;35. doi: 10.1007/s12035-013-8427-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-013-8427-5</ArticleId><ArticleId IdType="pmc">PMC3718993</ArticleId><ArticleId IdType="pubmed">23475610</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y.-F., Zhang Y.-J., Lin W.-L., Cao X., Stetler C., Dickson D.W., Lewis J., Petrucelli L. Expression of Mutant TDP-43 Induces Neuronal Dysfunction in Transgenic Mice. Mol. Neurodegener. 2011;6:73. doi: 10.1186/1750-1326-6-73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-6-73</ArticleId><ArticleId IdType="pmc">PMC3216869</ArticleId><ArticleId IdType="pubmed">22029574</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegorzewska I., Bell S., Cairns N.J., Miller T.M., Baloh R.H. TDP-43 Mutant Transgenic Mice Develop Features of ALS and Frontotemporal Lobar Degeneration. Proc. Natl. Acad. Sci. USA. 2009;106:18809&#x2013;18814. doi: 10.1073/pnas.0908767106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0908767106</ArticleId><ArticleId IdType="pmc">PMC2762420</ArticleId><ArticleId IdType="pubmed">19833869</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S.-L., Wu L.-S., Lee M., Chang C.-W., Cheng W.-C., Fang Y.-S., Chen Y.-R., Cheng P.-L., Shen C.-K.J. A Robust TDP-43 Knock-in Mouse Model of ALS. Acta Neuropathol. Commun. 2020;8:3. doi: 10.1186/s40478-020-0881-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-020-0881-5</ArticleId><ArticleId IdType="pmc">PMC6975031</ArticleId><ArticleId IdType="pubmed">31964415</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng H.-X., Jiang H., Fu R., Zhai H., Shi Y., Liu E., Hirano M., Dal Canto M.C., Siddique T. Molecular Dissection of ALS-Associated Toxicity of SOD1 in Transgenic Mice Using an Exon-Fusion Approach. Hum. Mol. Genet. 2008;17:2310&#x2013;2319. doi: 10.1093/hmg/ddn368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddn368</ArticleId><ArticleId IdType="pmc">PMC2465800</ArticleId><ArticleId IdType="pubmed">18424447</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong P.C., Pardo C.A., Borchelt D.R., Lee M.K., Copeland N.G., Jenkins N.A., Sisodia S.S., Cleveland D.W., Price D.L. An Adverse Property of a Familial ALS-Linked SOD1 Mutation Causes Motor Neuron Disease Characterized by Vacuolar Degeneration of Mitochondria. Neuron. 1995;14:1105&#x2013;1116. doi: 10.1016/0896-6273(95)90259-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(95)90259-7</ArticleId><ArticleId IdType="pubmed">7605627</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyn F.J., Li R., Kirk S.E., Tefera T.W., Xie T.Y., Tracey T.J., Kelk D., Wimberger E., Garton F.C., Roberts L., et al. Altered Skeletal Muscle Glucose&#x2013;Fatty Acid Flux in Amyotrophic Lateral Sclerosis. Brain Commun. 2020;2:fcaa154. doi: 10.1093/braincomms/fcaa154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcaa154</ArticleId><ArticleId IdType="pmc">PMC7677608</ArticleId><ArticleId IdType="pubmed">33241210</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L., Oudart H., Ren&#xe9; F., de Aguilar J.-L.G., Loeffler J.-P. Evidence for Defective Energy Homeostasis in Amyotrophic Lateral Sclerosis: Benefit of a High-Energy Diet in a Transgenic Mouse Model. Proc. Natl. Acad. Sci. USA. 2004;101:11159&#x2013;11164. doi: 10.1073/pnas.0402026101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0402026101</ArticleId><ArticleId IdType="pmc">PMC503756</ArticleId><ArticleId IdType="pubmed">15263088</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters O.M., Cabrera G.T., Tran H., Gendron T.F., McKeon J.E., Metterville J., Weiss A., Wightman N., Salameh J., Kim J., et al. Human C9ORF72 Hexanucleotide Expansion Reproduces RNA Foci and Dipeptide Repeat Proteins but Not Neurodegeneration in BAC Transgenic Mice. Neuron. 2015;88:902&#x2013;909. doi: 10.1016/j.neuron.2015.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.11.018</ArticleId><ArticleId IdType="pmc">PMC4828340</ArticleId><ArticleId IdType="pubmed">26637797</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke J.G., Bogdanik L., Muhammad A.K.M.G., Gendron T.F., Kim K.J., Austin A., Cady J., Liu E.Y., Zarrow J., Grant S., et al. C9orf72 BAC Transgenic Mice Display Typical Pathologic Features of ALS/FTD. Neuron. 2015;88:892&#x2013;901. doi: 10.1016/j.neuron.2015.10.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.10.027</ArticleId><ArticleId IdType="pmc">PMC4672384</ArticleId><ArticleId IdType="pubmed">26637796</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricketts T., McGoldrick P., Fratta P., de Oliveira H.M., Kent R., Phatak V., Brandner S., Blanco G., Greensmith L., Acevedo-Arozena A., et al. A Nonsense Mutation in Mouse Tardbp Affects TDP43 Alternative Splicing Activity and Causes Limb-Clasping and Body Tone Defects. PLoS ONE. 2014;9:e85962. doi: 10.1371/journal.pone.0085962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0085962</ArticleId><ArticleId IdType="pmc">PMC3897576</ArticleId><ArticleId IdType="pubmed">24465814</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S., Oiwa K., Murata Y., Komine O., Sobue A., Endo F., Takahashi E., Yamanaka K. ALS-Linked TDP-43M337V Knock-in Mice Exhibit Splicing Deregulation without Neurodegeneration. Mol. Brain. 2020;13:8. doi: 10.1186/s13041-020-0550-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-020-0550-4</ArticleId><ArticleId IdType="pmc">PMC6971932</ArticleId><ArticleId IdType="pubmed">31959210</ArticleId></ArticleIdList></Reference><Reference><Citation>White M.A., Kim E., Duffy A., Adalbert R., Phillips B.U., Peters O.M., Stephenson J., Yang S., Massenzio F., Lin Z., et al. TDP-43 Gains Function Due to Perturbed Autoregulation in a Tardbp Knock-in Mouse Model of ALS-FTD. Nat. Neurosci. 2018;21:552&#x2013;563. doi: 10.1038/s41593-018-0113-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0113-5</ArticleId><ArticleId IdType="pmc">PMC5884423</ArticleId><ArticleId IdType="pubmed">29556029</ArticleId></ArticleIdList></Reference><Reference><Citation>Watkins J.A., Alix J.J.P., Shaw P.J., Mead R.J. Extensive Phenotypic Characterisation of a Human TDP-43Q331K Transgenic Mouse Model of Amyotrophic Lateral Sclerosis (ALS) Sci. Rep. 2021;11:16659. doi: 10.1038/s41598-021-96122-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-96122-z</ArticleId><ArticleId IdType="pmc">PMC8370970</ArticleId><ArticleId IdType="pubmed">34404845</ArticleId></ArticleIdList></Reference><Reference><Citation>Stallings N.R., Puttaparthi K., Dowling K.J., Luther C.M., Burns D.K., Davis K., Elliott J.L. TDP-43, an ALS Linked Protein, Regulates Fat Deposition and Glucose Homeostasis. PLoS ONE. 2013;8:e71793. doi: 10.1371/journal.pone.0071793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0071793</ArticleId><ArticleId IdType="pmc">PMC3742534</ArticleId><ArticleId IdType="pubmed">23967244</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephenson J., Amor S. Modelling Amyotrophic Lateral Sclerosis in Mice. Drug Discov. Today Dis. Model. 2017;25&#x2013;26:35&#x2013;44. doi: 10.1016/j.ddmod.2018.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ddmod.2018.10.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaricamazza S., Salvatori I., Giacovazzo G., Loeffler J.P., Ren&#xe8; F., Rosina M., Quessada C., Proietti D., Heil C., Rossi S., et al. Skeletal-Muscle Metabolic Reprogramming in ALS-SOD1G93A Mice Predates Disease Onset and Is A Promising Therapeutic Target. iScience. 2020;23:101087. doi: 10.1016/j.isci.2020.101087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2020.101087</ArticleId><ArticleId IdType="pmc">PMC7200935</ArticleId><ArticleId IdType="pubmed">32371370</ArticleId></ArticleIdList></Reference><Reference><Citation>Smittkamp S.E., Morris J.K., Bomhoff G.L., Chertoff M.E., Geiger P.C., Stanford J.A. SOD1-G93A Mice Exhibit Muscle-Fiber-Type-Specific Decreases in Glucose Uptake in the Absence of Whole-Body Changes in Metabolism. Neurodegener. Dis. 2014;13:29&#x2013;37. doi: 10.1159/000351606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000351606</ArticleId><ArticleId IdType="pmc">PMC3970434</ArticleId><ArticleId IdType="pubmed">24021858</ArticleId></ArticleIdList></Reference><Reference><Citation>Tandan R., Levy E.A., Howard D.B., Hiser J., Kokinda N., Dey S., Kasarskis E.J. Body Composition in Amyotrophic Lateral Sclerosis Subjects and Its Effect on Disease Progression and Survival. Am. J. Clin. Nutr. 2022;115:1378&#x2013;1392. doi: 10.1093/ajcn/nqac016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcn/nqac016</ArticleId><ArticleId IdType="pmc">PMC9071423</ArticleId><ArticleId IdType="pubmed">35108352</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J.-Y., Sun X.-H., Cai Z.-Y., Shen D., Yang X.-Z., Liu M.-S., Cui L.-Y. Correlation of Weight and Body Composition with Disease Progression Rate in Patients with Amyotrophic Lateral Sclerosis. Sci. Rep. 2022;12:13292. doi: 10.1038/s41598-022-16229-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-16229-9</ArticleId><ArticleId IdType="pmc">PMC9345931</ArticleId><ArticleId IdType="pubmed">35918363</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindauer E., Dupuis L., M&#xfc;ller H.-P., Neumann H., Ludolph A.C., Kassubek J. Adipose Tissue Distribution Predicts Survival in Amyotrophic Lateral Sclerosis. PLoS ONE. 2013;8:e67783. doi: 10.1371/journal.pone.0067783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0067783</ArticleId><ArticleId IdType="pmc">PMC3694869</ArticleId><ArticleId IdType="pubmed">23826340</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman S.A., Boss J., Guo K., Alakwaa F.M., Patterson A., Kim S., Savelieff M.G., Hur J., Feldman E.L. Untargeted Metabolomics Yields Insight into ALS Disease Mechanisms. J. Neurol. Neurosurg. Psychiatry. 2020;91:1329&#x2013;1338. doi: 10.1136/jnnp-2020-323611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-323611</ArticleId><ArticleId IdType="pmc">PMC7677469</ArticleId><ArticleId IdType="pubmed">32928939</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingre C., Chen L., Zhan Y., Termorshuizen J., Yin L., Fang F. Lipids, Apolipoproteins, and Prognosis of Amyotrophic Lateral Sclerosis. Neurology. 2020;94:e1835&#x2013;e1844. doi: 10.1212/WNL.0000000000009322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000009322</ArticleId><ArticleId IdType="pmc">PMC7274849</ArticleId><ArticleId IdType="pubmed">32221024</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst J., K&#xfc;hnlein P., Hendrich C., Kassubek J., Sperfeld A.D., Ludolph A.C. Patients with Elevated Triglyceride and Cholesterol Serum Levels Have a Prolonged Survival in Amyotrophic Lateral Sclerosis. J. Neurol. 2011;258:613&#x2013;617. doi: 10.1007/s00415-010-5805-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-010-5805-z</ArticleId><ArticleId IdType="pubmed">21128082</ArticleId></ArticleIdList></Reference><Reference><Citation>Che&#x142;stowska B., Bara&#x144;czyk-Ku&#x17a;ma A., Ku&#x17a;ma-Kozakiewicz M. Dyslipidemia in Patients with Amyotrophic Lateral Sclerosis&#x2014;A Case Control Retrospective Study. Amyotroph. Lateral Scler. Front. Degener. 2021;22:195&#x2013;205. doi: 10.1080/21678421.2020.1832119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1832119</ArticleId><ArticleId IdType="pubmed">33103950</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H., Veyrat-Durebex C., Bocca C., Patin F., Vourc&#x2019;h P., Kouassi Nzoughet J., Lenaers G., Andres C.R., Simard G., Corcia P., et al. Lipidomics Reveals Cerebrospinal-Fluid Signatures of ALS. Sci. Rep. 2017;7:17652. doi: 10.1038/s41598-017-17389-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-17389-9</ArticleId><ArticleId IdType="pmc">PMC5732162</ArticleId><ArticleId IdType="pubmed">29247199</ArticleId></ArticleIdList></Reference><Reference><Citation>Area-Gomez E., Larrea D., Yun T., Xu Y., Hupf J., Zandkarimi F., Chan R.B., Mitsumoto H. Lipidomics Study of Plasma from Patients Suggest That ALS and PLS Are Part of a Continuum of Motor Neuron Disorders. Sci. Rep. 2021;11:13562. doi: 10.1038/s41598-021-92112-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-92112-3</ArticleId><ArticleId IdType="pmc">PMC8245424</ArticleId><ArticleId IdType="pubmed">34193885</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Luo X., Chen X., Shang H. Lipid Profile in Patients With Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis. Front. Neurol. 2020;11:567753. doi: 10.3389/fneur.2020.567753.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.567753</ArticleId><ArticleId IdType="pmc">PMC7593382</ArticleId><ArticleId IdType="pubmed">33178110</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal I., Lim Y.S., Ng S.-Y., Ling S.-C. Deciphering Lipid Dysregulation in ALS: From Mechanisms to Translational Medicine. Transl. Neurodegener. 2022;11:48. doi: 10.1186/s40035-022-00322-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-022-00322-0</ArticleId><ArticleId IdType="pmc">PMC9641964</ArticleId><ArticleId IdType="pubmed">36345044</ArticleId></ArticleIdList></Reference><Reference><Citation>Godoy-Corchuelo J.M., Fern&#xe1;ndez-Beltr&#xe1;n L.C., Ali Z., Gil-Moreno M.J., L&#xf3;pez-Carbonero J.I., Guerrero-Sola A., Larrad-Sainz A., Matias-Guiu J., Matias-Guiu J.A., Cunningham T.J., et al. Lipid Metabolic Alterations in the ALS-FTD Spectrum of Disorders. Biomedicines. 2022;10:1105. doi: 10.3390/biomedicines10051105.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10051105</ArticleId><ArticleId IdType="pmc">PMC9138405</ArticleId><ArticleId IdType="pubmed">35625841</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge J.C., Treleaven C.M., Pacheco J., Cooper S., Bao C., Abraham M., Cromwell M., Sardi S.P., Chuang W.-L., Sidman R.L., et al. Glycosphingolipids Are Modulators of Disease Pathogenesis in Amyotrophic Lateral Sclerosis. Proc. Natl. Acad. Sci. USA. 2015;112:8100&#x2013;8105. doi: 10.1073/pnas.1508767112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1508767112</ArticleId><ArticleId IdType="pmc">PMC4491749</ArticleId><ArticleId IdType="pubmed">26056266</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S.-M., Kim H., Kim J.-E., Park K.S., Sung J.-J., Kim S.H., Lee K.-W. Amyotrophic Lateral Sclerosis Is Associated with Hypolipidemia at the Presymptomatic Stage in Mice. PLoS ONE. 2011;6:e17985. doi: 10.1371/journal.pone.0017985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0017985</ArticleId><ArticleId IdType="pmc">PMC3064597</ArticleId><ArticleId IdType="pubmed">21464953</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriques A., Croixmarie V., Priestman D.A., Rosenbohm A., Dirrig-Grosch S., D&#x2019;Ambra E., Huebecker M., Hussain G., Boursier-Neyret C., Echaniz-Laguna A., et al. Amyotrophic Lateral Sclerosis and Denervation Alter Sphingolipids and Up-Regulate Glucosylceramide Synthase. Hum. Mol. Genet. 2015;24:7390&#x2013;7405. doi: 10.1093/hmg/ddv439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv439</ArticleId><ArticleId IdType="pmc">PMC4664174</ArticleId><ArticleId IdType="pubmed">26483191</ArticleId></ArticleIdList></Reference><Reference><Citation>Burg T., Rossaert E., Moisse M., Van Damme P., Van Den Bosch L. Histone Deacetylase Inhibition Regulates Lipid Homeostasis in a Mouse Model of Amyotrophic Lateral Sclerosis. Int. J. Mol. Sci. 2021;22:11224. doi: 10.3390/ijms222011224.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222011224</ArticleId><ArticleId IdType="pmc">PMC8541517</ArticleId><ArticleId IdType="pubmed">34681883</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagani M., Chi&#xf2; A., Valentini M.C., &#xd6;berg J., Nobili F., Calvo A., Moglia C., Bertuzzo D., Morbelli S., De Carli F., et al. Functional Pattern of Brain FDG-PET in Amyotrophic Lateral Sclerosis. Neurology. 2014;83:1067&#x2013;1074. doi: 10.1212/WNL.0000000000000792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000792</ArticleId><ArticleId IdType="pubmed">25122207</ArticleId></ArticleIdList></Reference><Reference><Citation>Weerasekera A., Crabb&#xe9; M., Tom&#xe9; S.O., Gsell W., Sima D., Casteels C., Dresselaers T., Deroose C., Van Huffel S., Rudolf Thal D., et al. Non-Invasive Characterization of Amyotrophic Lateral Sclerosis in a HTDP-43A315T Mouse Model: A PET-MR Study. Neuroimage Clin. 2020;27:102327. doi: 10.1016/j.nicl.2020.102327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2020.102327</ArticleId><ArticleId IdType="pmc">PMC7352080</ArticleId><ArticleId IdType="pubmed">32653817</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazaki K., Masamoto K., Morimoto N., Kurata T., Mimoto T., Obata T., Kanno I., Abe K. Early and Progressive Impairment of Spinal Blood Flow&#x2013;Glucose Metabolism Coupling in Motor Neuron Degeneration of ALS Model Mice. J. Cereb. Blood Flow Metab. 2012;32:456&#x2013;467. doi: 10.1038/jcbfm.2011.155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.2011.155</ArticleId><ArticleId IdType="pmc">PMC3293114</ArticleId><ArticleId IdType="pubmed">22068226</ArticleId></ArticleIdList></Reference><Reference><Citation>Palamiuc L., Schlagowski A., Ngo S.T., Vernay A., Dirrig-Grosch S., Henriques A., Boutillier A.-L., Zoll J., Echaniz-Laguna A., Loeffler J.-P., et al. A Metabolic Switch toward Lipid Use in Glycolytic Muscle Is an Early Pathologic Event in a Mouse Model of Amyotrophic Lateral Sclerosis. EMBO Mol. Med. 2015;7:526&#x2013;546. doi: 10.15252/emmm.201404433.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201404433</ArticleId><ArticleId IdType="pmc">PMC4492815</ArticleId><ArticleId IdType="pubmed">25820275</ArticleId></ArticleIdList></Reference><Reference><Citation>Browne S.E., Yang L., DiMauro J.-P., Fuller S.W., Licata S.C., Beal M.F. Bioenergetic Abnormalities in Discrete Cerebral Motor Pathways Presage Spinal Cord Pathology in the G93A SOD1 Mouse Model of ALS. Neurobiol. Dis. 2006;22:599&#x2013;610. doi: 10.1016/j.nbd.2006.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2006.01.001</ArticleId><ArticleId IdType="pubmed">16616851</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S., Saporta S., Haller E., Kolomey I., Bennett S.P., Potter H., Sanberg P.R. Evidence of Compromised Blood-Spinal Cord Barrier in Early and Late Symptomatic SOD1 Mice Modeling ALS. PLoS ONE. 2007;2:e1205. doi: 10.1371/journal.pone.0001205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0001205</ArticleId><ArticleId IdType="pmc">PMC2075163</ArticleId><ArticleId IdType="pubmed">18030339</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano Y., Hirayama K., Terao K. Hepatic Ultrastructural Changes and Liver Dysfunction in Amyotrophic Lateral Sclerosis. Arch. Neurol. 1987;44:103&#x2013;106. doi: 10.1001/archneur.1987.00520130079022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1987.00520130079022</ArticleId><ArticleId IdType="pubmed">3800708</ArticleId></ArticleIdList></Reference><Reference><Citation>Nodera H., Takamatsu N., Muguruma N., Ukimoto K., Nishio S., Oda M., Izumi Y., Kaji R. Frequent Hepatic Steatosis in Amyotrophic Lateral Sclerosis: Implication for Systemic Involvement. Neurol. Clin. Neurosci. 2015;3:58&#x2013;62. doi: 10.1111/ncn3.143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ncn3.143</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkelstein A., Kunis G., Seksenyan A., Ronen A., Berkutzki T., Azoulay D., Koronyo-Hamaoui M., Schwartz M. Abnormal Changes in NKT Cells, the IGF-1 Axis, and Liver Pathology in an Animal Model of ALS. PLoS ONE. 2011;6:e22374. doi: 10.1371/journal.pone.0022374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0022374</ArticleId><ArticleId IdType="pmc">PMC3149057</ArticleId><ArticleId IdType="pubmed">21829620</ArticleId></ArticleIdList></Reference><Reference><Citation>Araki K., Araki A., Honda D., Izumoto T., Hashizume A., Hijikata Y., Yamada S., Iguchi Y., Hara A., Ikumi K., et al. TDP-43 Regulates Early-Phase Insulin Secretion via CaV1.2-Mediated Exocytosis in Islets. J. Clin. Investig. 2019;129:3578&#x2013;3593. doi: 10.1172/JCI124481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI124481</ArticleId><ArticleId IdType="pmc">PMC6715357</ArticleId><ArticleId IdType="pubmed">31355778</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald T.S., Kumar V., Fung J.N., Woodruff T.M., Lee J.D. Glucose Clearance and Uptake Is Increased in the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis through an Insulin-Independent Mechanism. FASEB J. 2021;35:e21707. doi: 10.1096/fj.202002450R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.202002450R</ArticleId><ArticleId IdType="pubmed">34118098</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorges M., Vercruysse P., M&#xfc;ller H.-P., Huppertz H.-J., Rosenbohm A., Nagel G., Weydt P., Peters&#xe9;n &#xc5;., Ludolph A.C., Kassubek J., et al. Hypothalamic Atrophy Is Related to Body Mass Index and Age at Onset in Amyotrophic Lateral Sclerosis. J. Neurol. Neurosurg. Psychiatry. 2017;88:1033&#x2013;1041. doi: 10.1136/jnnp-2017-315795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-315795</ArticleId><ArticleId IdType="pubmed">28596251</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S., Ren Q., Gong G., Sun Y., Zhao B., Ma X., Zhang N., Zhong S., Lin Y., Wang W., et al. Hypothalamic Subregion Abnormalities Are Related to Body Mass Index in Patients with Sporadic Amyotrophic Lateral Sclerosis. J. Neurol. 2022;269:2980&#x2013;2988. doi: 10.1007/s00415-021-10900-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10900-3</ArticleId><ArticleId IdType="pubmed">34779889</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang J., Shaw T.B., Holdom C.J., McCombe P.A., Henderson R.D., Fripp J., Barth M., Guo C.C., Ngo S.T., Steyn F.J., et al. Lower Hypothalamic Volume with Lower Body Mass Index Is Associated with Shorter Survival in Patients with Amyotrophic Lateral Sclerosis. Eur. J. Neurol. 2022;30:57&#x2013;68. doi: 10.1111/ene.15589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15589</ArticleId><ArticleId IdType="pmc">PMC10099625</ArticleId><ArticleId IdType="pubmed">36214080</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye S., Luo Y., Jin P., Wang Y., Zhang N., Zhang G., Chen L., Shi L., Fan D. MRI Volumetric Analysis of the Thalamus and Hypothalamus in Amyotrophic Lateral Sclerosis. Front. Aging Neurosci. 2022;13:858. doi: 10.3389/fnagi.2021.610332.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2021.610332</ArticleId><ArticleId IdType="pmc">PMC8763328</ArticleId><ArticleId IdType="pubmed">35046789</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayer D., Antonucci S., M&#xfc;ller H.-P., Saad R., Dupuis L., Rasche V., B&#xf6;ckers T.M., Ludolph A.C., Kassubek J., Roselli F. Disruption of Orbitofrontal-Hypothalamic Projections in a Murine ALS Model and in Human Patients. Transl. Neurodegener. 2021;10:17. doi: 10.1186/s40035-021-00241-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-021-00241-6</ArticleId><ArticleId IdType="pmc">PMC8168014</ArticleId><ArticleId IdType="pubmed">34059131</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngo S.T., van Eijk R.P.A., Chachay V., van den Berg L.H., McCombe P.A., Henderson R.D., Steyn F.J. Loss of Appetite Is Associated with a Loss of Weight and Fat Mass in Patients with Amyotrophic Lateral Sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2019;20:497&#x2013;505. doi: 10.1080/21678421.2019.1621346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1621346</ArticleId><ArticleId IdType="pubmed">31144522</ArticleId></ArticleIdList></Reference><Reference><Citation>Vercruysse P., Sinniger J., El Oussini H., Scekic-Zahirovic J., Dieterl&#xe9; S., Dengler R., Meyer T., Zierz S., Kassubek J., Fischer W., et al. Alterations in the Hypothalamic Melanocortin Pathway in Amyotrophic Lateral Sclerosis. Brain. 2016;139:1106&#x2013;1122. doi: 10.1093/brain/aww004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww004</ArticleId><ArticleId IdType="pubmed">26984187</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker J.S., McCormick M.C., Robergs R.A. Interaction among Skeletal Muscle Metabolic Energy Systems during Intense Exercise. J. Nutr. Metab. 2010;2010:905612. doi: 10.1155/2010/905612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2010/905612</ArticleId><ArticleId IdType="pmc">PMC3005844</ArticleId><ArticleId IdType="pubmed">21188163</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss M., Kaddurah-Daouk R. Creatine and Creatinine Metabolism. Physiol. Rev. 2000;80:1107&#x2013;1213. doi: 10.1152/physrev.2000.80.3.1107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.2000.80.3.1107</ArticleId><ArticleId IdType="pubmed">10893433</ArticleId></ArticleIdList></Reference><Reference><Citation>Baxmann A.C., Ahmed M.S., Marques N.C., Menon V.B., Pereira A.B., Kirsztajn G.M., Heilberg I.P. Influence of Muscle Mass and Physical Activity on Serum and Urinary Creatinine and Serum Cystatin C. Clin. J. Am. Soc. Nephrol. 2008;3:348&#x2013;354. doi: 10.2215/CJN.02870707.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.02870707</ArticleId><ArticleId IdType="pmc">PMC2390952</ArticleId><ArticleId IdType="pubmed">18235143</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Luo X., Chen X., Shang H. Serum Creatinine Levels in Patients with Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis. Amyotroph. Lateral Scler. Front. Degener. 2020;21:502&#x2013;508. doi: 10.1080/21678421.2020.1774610.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1774610</ArticleId><ArticleId IdType="pubmed">32564621</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao J., Dharmadasa T., Malaspina A., Shaw P.J., Talbot K., Turner M.R., Thompson A.G. Creatine Kinase and Prognosis in Amyotrophic Lateral Sclerosis: A Literature Review and Multi-Centre Cohort Analysis. J. Neurol. 2022;269:5395&#x2013;5404. doi: 10.1007/s00415-022-11195-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-022-11195-8</ArticleId><ArticleId IdType="pmc">PMC9467954</ArticleId><ArticleId IdType="pubmed">35614165</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X.-P., Wei Q.-Q., Ou R.-W., Hou Y.-B., Zhang L.-Y., Yuan X.-Q., Yao Y.-Q., Jia D.-S., Zhang Q., Li W.-X., et al. Creatine Kinase in the Diagnosis and Prognostic Prediction of Amyotrophic Lateral Sclerosis: A Retrospective Case-Control Study. Neural Regen. Res. 2021;16:591&#x2013;595. doi: 10.4103/1673-5374.293159.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.293159</ArticleId><ArticleId IdType="pmc">PMC7996010</ArticleId><ArticleId IdType="pubmed">32985493</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q., Hu W., Xu L., Luo H., Wang N., Zhang Q. Decreased Serum Creatinine Levels Predict Short Survival in Amyotrophic Lateral Sclerosis. Ann. Clin. Transl. Neurol. 2021;8:448&#x2013;455. doi: 10.1002/acn3.51299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51299</ArticleId><ArticleId IdType="pmc">PMC7886033</ArticleId><ArticleId IdType="pubmed">33449454</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenfeld J., King R.M., Jackson C.E., Bedlack R.S., Barohn R.J., Dick A., Phillips L.H., Chapin J., Gelinas D.F., Lou J.-S. Creatine Monohydrate in ALS: Effects on Strength, Fatigue, Respiratory Status and ALSFRS. Amyotroph. Lateral Scler. 2008;9:266&#x2013;272. doi: 10.1080/17482960802028890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802028890</ArticleId><ArticleId IdType="pmc">PMC2631354</ArticleId><ArticleId IdType="pubmed">18608103</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner J.M., Cudkowicz M.E., Schoenfeld D., Conrad T., Taft J., Chilton M., Urbinelli L., Qureshi M., Zhang H., Pestronk A., et al. A Clinical Trial of Creatine in ALS. Neurology. 2004;63:1656&#x2013;1661. doi: 10.1212/01.WNL.0000142992.81995.F0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000142992.81995.F0</ArticleId><ArticleId IdType="pubmed">15534251</ArticleId></ArticleIdList></Reference><Reference><Citation>Nijssen J., Comley L.H., Hedlund E. Motor Neuron Vulnerability and Resistance in Amyotrophic Lateral Sclerosis. Acta Neuropathol. 2017;133:863&#x2013;885. doi: 10.1007/s00401-017-1708-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1708-8</ArticleId><ArticleId IdType="pmc">PMC5427160</ArticleId><ArticleId IdType="pubmed">28409282</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey D., Schneider C., Xu L., Borg J., Spooren W., Caroni P. Early and Selective Loss of Neuromuscular Synapse Subtypes with Low Sprouting Competence in Motoneuron Diseases. J. Neurosci. 2000;20:2534&#x2013;2542. doi: 10.1523/JNEUROSCI.20-07-02534.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.20-07-02534.2000</ArticleId><ArticleId IdType="pmc">PMC6772256</ArticleId><ArticleId IdType="pubmed">10729333</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferri A., Coccurello R. What Is &#x201c;Hyper&#x201d; in the ALS Hypermetabolism? Mediat. Inflamm. 2017;2017:e7821672. doi: 10.1155/2017/7821672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/7821672</ArticleId><ArticleId IdType="pmc">PMC5610793</ArticleId><ArticleId IdType="pubmed">29081604</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiaffino S., Reggiani C. Fiber Types in Mammalian Skeletal Muscles. Physiol. Rev. 2011;91:1447&#x2013;1531. doi: 10.1152/physrev.00031.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00031.2010</ArticleId><ArticleId IdType="pubmed">22013216</ArticleId></ArticleIdList></Reference><Reference><Citation>Hegedus J., Putman C.T., Gordon T. Time Course of Preferential Motor Unit Loss in the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis. Neurobiol. Dis. 2007;28:154&#x2013;164. doi: 10.1016/j.nbd.2007.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2007.07.003</ArticleId><ArticleId IdType="pubmed">17766128</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Cruz S., Parone P.A., Lopes V.S., Lillo C., McAlonis-Downes M., Lee S.K., Vetto A.P., Petrosyan S., Marsala M., Murphy A.N., et al. Elevated PGC-1&#x3b1; Activity Sustains Mitochondrial Biogenesis and Muscle Function without Extending Survival in a Mouse Model of Inherited ALS. Cell Metab. 2012;15:778&#x2013;786. doi: 10.1016/j.cmet.2012.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2012.03.019</ArticleId><ArticleId IdType="pmc">PMC3565468</ArticleId><ArticleId IdType="pubmed">22560226</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy O.T., Czech M.P., Corvera S. What Causes the Insulin Resistance Underlying Obesity? Curr. Opin. Endocrinol. Diabetes Obes. 2012;19:81&#x2013;87. doi: 10.1097/MED.0b013e3283514e13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MED.0b013e3283514e13</ArticleId><ArticleId IdType="pmc">PMC4038351</ArticleId><ArticleId IdType="pubmed">22327367</ArticleId></ArticleIdList></Reference><Reference><Citation>Makki K., Froguel P., Wolowczuk I. Adipose Tissue in Obesity-Related Inflammation and Insulin Resistance: Cells, Cytokines, and Chemokines. ISRN Inflamm. 2013;2013:139239. doi: 10.1155/2013/139239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/139239</ArticleId><ArticleId IdType="pmc">PMC3881510</ArticleId><ArticleId IdType="pubmed">24455420</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard A.J., White U., Elks C.M., Stephens J.M. Adipose Tissue: Physiology to Metabolic Dysfunction. In: Feingold K.R., Anawalt B., Boyce A., Chrousos G., de Herder W.W., Dhatariya K., Dungan K., Hershman J.M., Hofland J., Kalra S., et al., editors. Endotext [Internet] MDText.com, Inc.; South Dartmouth, MA, USA: 2000.</Citation><ArticleIdList><ArticleId IdType="pubmed">32255578</ArticleId></ArticleIdList></Reference><Reference><Citation>Harms M., Seale P. Brown and Beige Fat: Development, Function and Therapeutic Potential. Nat. Med. 2013;19:1252&#x2013;1263. doi: 10.1038/nm.3361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3361</ArticleId><ArticleId IdType="pubmed">24100998</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend K., Tseng Y.-H. Brown Adipose Tissue. Adipocyte. 2012;1:13&#x2013;24. doi: 10.4161/adip.18951.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/adip.18951</ArticleId><ArticleId IdType="pmc">PMC3661118</ArticleId><ArticleId IdType="pubmed">23700507</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamucci K.A., Namwanje M., Fan L., Qiang L. The Dark Side of Browning. Protein Cell. 2018;9:152&#x2013;163. doi: 10.1007/s13238-017-0434-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-017-0434-2</ArticleId><ArticleId IdType="pmc">PMC5818365</ArticleId><ArticleId IdType="pubmed">28677104</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciccarone F., Castelli S., Lazzarino G., Scaricamazza S., Mangione R., Bernardini S., Apolloni S., D&#x2019;Ambrosi N., Ferri A., Ciriolo M.R. Lipid Catabolism and Mitochondrial Uncoupling Are Stimulated in Brown Adipose Tissue of Amyotrophic Lateral Sclerosis Mouse Models. Genes Dis. 2022;10:321&#x2013;324. doi: 10.1016/j.gendis.2022.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gendis.2022.04.006</ArticleId><ArticleId IdType="pmc">PMC10201591</ArticleId><ArticleId IdType="pubmed">37223542</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaves-Filho A.B., Pinto I.F.D., Dantas L.S., Xavier A.M., Inague A., Faria R.L., Medeiros M.H.G., Glezer I., Yoshinaga M.Y., Miyamoto S. Alterations in Lipid Metabolism of Spinal Cord Linked to Amyotrophic Lateral Sclerosis. Sci. Rep. 2019;9:11642. doi: 10.1038/s41598-019-48059-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-48059-7</ArticleId><ArticleId IdType="pmc">PMC6691112</ArticleId><ArticleId IdType="pubmed">31406145</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L., Corcia P., Fergani A., Aguilar J.-L.G.D., Bonnefont-Rousselot D., Bittar R., Seilhean D., Hauw J.-J., Lacomblez L., Loeffler J.-P., et al. Dyslipidemia Is a Protective Factor in Amyotrophic Lateral Sclerosis. Neurology. 2008;70:1004&#x2013;1009. doi: 10.1212/01.wnl.0000285080.70324.27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000285080.70324.27</ArticleId><ArticleId IdType="pubmed">18199832</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J., Yang G., Kim Y., Kim J., Ha J. AMPK Activators: Mechanisms of Action and Physiological Activities. Exp. Mol. Med. 2016;48:e224. doi: 10.1038/emm.2016.16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emm.2016.16</ArticleId><ArticleId IdType="pmc">PMC4855276</ArticleId><ArticleId IdType="pubmed">27034026</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon S.-M. Regulation and Function of AMPK in Physiology and Diseases. Exp. Mol. Med. 2016;48:e245. doi: 10.1038/emm.2016.81.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emm.2016.81</ArticleId><ArticleId IdType="pmc">PMC4973318</ArticleId><ArticleId IdType="pubmed">27416781</ArticleId></ArticleIdList></Reference><Reference><Citation>Perera N.D., Sheean R.K., Scott J.W., Kemp B.E., Horne M.K., Turner B.J. Mutant TDP-43 Deregulates AMPK Activation by PP2A in ALS Models. PLoS ONE. 2014;9:e90449. doi: 10.1371/journal.pone.0090449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0090449</ArticleId><ArticleId IdType="pmc">PMC3942426</ArticleId><ArticleId IdType="pubmed">24595038</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim M.A., Selak M.A., Xiang Z., Krainc D., Neve R.L., Kraemer B.C., Watts J.L., Kalb R.G. Reduced Activity of AMP-Activated Protein Kinase Protects against Genetic Models of Motor Neuron Disease. J. Neurosci. 2012;32:1123&#x2013;1141. doi: 10.1523/JNEUROSCI.6554-10.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.6554-10.2012</ArticleId><ArticleId IdType="pmc">PMC3742882</ArticleId><ArticleId IdType="pubmed">22262909</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradat P.-F., Bruneteau G., Gordon P.H., Dupuis L., Bonnefont-Rousselot D., Simon D., Salachas F., Corcia P., Frochot V., Lacorte J.-M., et al. Impaired Glucose Tolerance in Patients with Amyotrophic Lateral Sclerosis. Amyotroph. Lateral Scler. 2010;11:166&#x2013;171. doi: 10.3109/17482960902822960.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960902822960</ArticleId><ArticleId IdType="pubmed">20184518</ArticleId></ArticleIdList></Reference><Reference><Citation>Charchaflie R.J., Fernandez L.B., Perec C.J., Gonzalez E., Marzi A. Functional Studies of the Parotid and Pancreas Glands in Amyotrophic Lateral Sclerosis. J. Neurol. Neurosurg. Psychiatry. 1974;37:863&#x2013;867. doi: 10.1136/jnnp.37.7.863.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.37.7.863</ArticleId><ArticleId IdType="pmc">PMC494795</ArticleId><ArticleId IdType="pubmed">4852110</ArticleId></ArticleIdList></Reference><Reference><Citation>Quick D.T., Greer M. Pancreatic Dysfunction in Patients with Amyotrophic Lateral Sclerosis. Neurology. 1967;17:112. doi: 10.1212/WNL.17.2.112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.17.2.112</ArticleId><ArticleId IdType="pubmed">6066871</ArticleId></ArticleIdList></Reference><Reference><Citation>Mink J.W., Blumenschine R.J., Adams D.B. Ratio of Central Nervous System to Body Metabolism in Vertebrates: Its Constancy and Functional Basis. Am. J. Physiol. 1981;241:R203&#x2013;R212. doi: 10.1152/ajpregu.1981.241.3.R203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpregu.1981.241.3.R203</ArticleId><ArticleId IdType="pubmed">7282965</ArticleId></ArticleIdList></Reference><Reference><Citation>Herculano-Houzel S. The Remarkable, yet Not Extraordinary, Human Brain as a Scaled-up Primate Brain and Its Associated Cost. Proc. Natl. Acad. Sci. USA. 2012;109:10661&#x2013;10668. doi: 10.1073/pnas.1201895109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1201895109</ArticleId><ArticleId IdType="pmc">PMC3386878</ArticleId><ArticleId IdType="pubmed">22723358</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyder F., Rothman D.L., Bennett M.R. Cortical Energy Demands of Signaling and Nonsignaling Components in Brain Are Conserved across Mammalian Species and Activity Levels. Proc. Natl. Acad. Sci. USA. 2013;110:3549&#x2013;3554. doi: 10.1073/pnas.1214912110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1214912110</ArticleId><ArticleId IdType="pmc">PMC3587194</ArticleId><ArticleId IdType="pubmed">23319606</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallermann S., de Kock C.P.J., Stuart G.J., Kole M.H.P. State and Location Dependence of Action Potential Metabolic Cost in Cortical Pyramidal Neurons. Nat. Neurosci. 2012;15:1007&#x2013;1014. doi: 10.1038/nn.3132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3132</ArticleId><ArticleId IdType="pubmed">22660478</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng Z.-H. The Interplay of Axonal Energy Homeostasis and Mitochondrial Trafficking and Anchoring. Trends Cell Biol. 2017;27:403&#x2013;416. doi: 10.1016/j.tcb.2017.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcb.2017.01.005</ArticleId><ArticleId IdType="pmc">PMC5440189</ArticleId><ArticleId IdType="pubmed">28228333</ArticleId></ArticleIdList></Reference><Reference><Citation>Chamberlain K.A., Sheng Z.-H. Mechanisms for the Maintenance and Regulation of Axonal Energy Supply. J. Neurosci. Res. 2019;97:897&#x2013;913. doi: 10.1002/jnr.24411.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.24411</ArticleId><ArticleId IdType="pmc">PMC6565461</ArticleId><ArticleId IdType="pubmed">30883896</ArticleId></ArticleIdList></Reference><Reference><Citation>Mergenthaler P., Lindauer U., Dienel G.A., Meisel A. Sugar for the Brain: The Role of Glucose in Physiological and Pathological Brain Function. Trends Neurosci. 2013;36:587&#x2013;597. doi: 10.1016/j.tins.2013.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2013.07.001</ArticleId><ArticleId IdType="pmc">PMC3900881</ArticleId><ArticleId IdType="pubmed">23968694</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzo E., Lorenzini I., Barrameda D., O&#x2019;Conner A.G., Barrows J.M., Starr A., Kovalik T., Rabichow B.E., Lehmkuhl E.M., Shreiner D.D., et al. Glycolysis Upregulation Is Neuroprotective as a Compensatory Mechanism in ALS. eLife. 2019;8:e45114. doi: 10.7554/eLife.45114.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.45114</ArticleId><ArticleId IdType="pmc">PMC6557627</ArticleId><ArticleId IdType="pubmed">31180318</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler R.G., Pedersen W.A., Camandola S., Rothstein J.D., Mattson M.P. Evidence That Accumulation of Ceramides and Cholesterol Esters Mediates Oxidative Stress-Induced Death of Motor Neurons in Amyotrophic Lateral Sclerosis. Ann. Neurol. 2002;52:448&#x2013;457. doi: 10.1002/ana.10312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10312</ArticleId><ArticleId IdType="pubmed">12325074</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzo E., O&#x2019;Conner A.G., Barrows J.M., Shreiner D.D., Birchak G.J., Zarnescu D.C. Medium-Chain Fatty Acids, Beta-Hydroxybutyric Acid and Genetic Modulation of the Carnitine Shuttle Are Protective in a Drosophila Model of ALS Based on TDP-43. Front. Mol. Neurosci. 2018;11:182. doi: 10.3389/fnmol.2018.00182.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2018.00182</ArticleId><ArticleId IdType="pmc">PMC5990617</ArticleId><ArticleId IdType="pubmed">29904341</ArticleId></ArticleIdList></Reference><Reference><Citation>Egawa N., Izumi Y., Suzuki H., Tsuge I., Fujita K., Shimano H., Izumikawa K., Takahashi N., Tsukita K., Enami T., et al. TDP-43 Regulates Cholesterol Biosynthesis by Inhibiting Sterol Regulatory Element-Binding Protein 2. Sci. Rep. 2022;12:7988. doi: 10.1038/s41598-022-12133-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-12133-4</ArticleId><ArticleId IdType="pmc">PMC9107471</ArticleId><ArticleId IdType="pubmed">35568729</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H., Lee J.J., Park N.Y., Dubey S.K., Kim T., Ruan K., Lim S.B., Park S.-H., Ha S., Kovlyagina I., et al. Multi-Omic Analysis of Selectively Vulnerable Motor Neuron Subtypes Implicates Altered Lipid Metabolism in ALS. Nat. Neurosci. 2021;24:1673&#x2013;1685. doi: 10.1038/s41593-021-00944-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-021-00944-z</ArticleId><ArticleId IdType="pmc">PMC8639773</ArticleId><ArticleId IdType="pubmed">34782793</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattiazzi M., D&#x2019;Aurelio M., Gajewski C.D., Martushova K., Kiaei M., Beal M.F., Manfredi G. Mutated Human SOD1 Causes Dysfunction of Oxidative Phosphorylation in Mitochondria of Transgenic Mice. J. Biol. Chem. 2002;277:29626&#x2013;29633. doi: 10.1074/jbc.M203065200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M203065200</ArticleId><ArticleId IdType="pubmed">12050154</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins C.M.J., Jung C., Ding H., Xu Z. Mutant Cu, Zn Superoxide Dismutase That Causes Motoneuron Degeneration Is Present in Mitochondria in the CNS. J. Neurosci. 2002;22:RC215. doi: 10.1523/JNEUROSCI.22-06-j0001.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.22-06-j0001.2002</ArticleId><ArticleId IdType="pmc">PMC6758252</ArticleId><ArticleId IdType="pubmed">11886899</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng J., Wang P., Chen X., Cheng H., Liu J., Fushimi K., Zhu L., Wu J.Y. FUS Interacts with ATP Synthase Beta Subunit and Induces Mitochondrial Unfolded Protein Response in Cellular and Animal Models. Proc. Natl. Acad. Sci. USA. 2018;115:E9678&#x2013;E9686. doi: 10.1073/pnas.1806655115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1806655115</ArticleId><ArticleId IdType="pmc">PMC6187197</ArticleId><ArticleId IdType="pubmed">30249657</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakaya T., Maragkakis M. Amyotrophic Lateral Sclerosis Associated FUS Mutation Shortens Mitochondria and Induces Neurotoxicity. Sci. Rep. 2018;8:15575. doi: 10.1038/s41598-018-33964-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-33964-0</ArticleId><ArticleId IdType="pmc">PMC6197261</ArticleId><ArticleId IdType="pubmed">30349096</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W., Li L., Lin W.-L., Dickson D.W., Petrucelli L., Zhang T., Wang X. The ALS Disease-Associated Mutant TDP-43 Impairs Mitochondrial Dynamics and Function in Motor Neurons. Hum. Mol. Genet. 2013;22:4706&#x2013;4719. doi: 10.1093/hmg/ddt319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt319</ArticleId><ArticleId IdType="pmc">PMC3820133</ArticleId><ArticleId IdType="pubmed">23827948</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu C.-H., Davidson S., Harapas C.R., Hilton J.B., Mlodzianoski M.J., Laohamonthonkul P., Louis C., Low R.R.J., Moecking J., De Nardo D., et al. TDP-43 Triggers Mitochondrial DNA Release via MPTP to Activate CGAS/STING in ALS. Cell. 2020;183:636&#x2013;649.e18. doi: 10.1016/j.cell.2020.09.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.020</ArticleId><ArticleId IdType="pmc">PMC7599077</ArticleId><ArticleId IdType="pubmed">33031745</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Suaga P., M&#xf3;rotz G.M., Markovinovic A., Mart&#xed;n-Guerrero S.M., Preza E., Arias N., Mayl K., Aabdien A., Gesheva V., Nishimura A., et al. Disruption of ER-Mitochondria Tethering and Signalling in C9orf72-Associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Aging Cell. 2022;21:e13549. doi: 10.1111/acel.13549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.13549</ArticleId><ArticleId IdType="pmc">PMC8844122</ArticleId><ArticleId IdType="pubmed">35026048</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta A.R., Gregory J.M., Dando O., Carter R.N., Burr K., Nanda J., Story D., McDade K., Smith C., Morton N.M., et al. Mitochondrial Bioenergetic Deficits in C9orf72 Amyotrophic Lateral Sclerosis Motor Neurons Cause Dysfunctional Axonal Homeostasis. Acta Neuropathol. 2021;141:257&#x2013;279. doi: 10.1007/s00401-020-02252-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02252-5</ArticleId><ArticleId IdType="pmc">PMC7847443</ArticleId><ArticleId IdType="pubmed">33398403</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi S.Y., Lopez-Gonzalez R., Krishnan G., Phillips H.L., Li A.N., Seeley W.W., Yao W.-D., Almeida S., Gao F.-B. C9ORF72-ALS/FTD-Associated Poly(GR) Binds Atp5a1 and Compromises Mitochondrial Function in Vivo. Nat. Neurosci. 2019;22:851&#x2013;862. doi: 10.1038/s41593-019-0397-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0397-0</ArticleId><ArticleId IdType="pmc">PMC6800116</ArticleId><ArticleId IdType="pubmed">31086314</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferri A., Cozzolino M., Crosio C., Nencini M., Casciati A., Gralla E.B., Rotilio G., Valentine J.S., Carr&#xec; M.T. Familial ALS-Superoxide Dismutases Associate with Mitochondria and Shift Their Redox Potentials. Proc. Natl. Acad. Sci. USA. 2006;103:13860&#x2013;13865. doi: 10.1073/pnas.0605814103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0605814103</ArticleId><ArticleId IdType="pmc">PMC1557633</ArticleId><ArticleId IdType="pubmed">16945901</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi L., Ke Y., Luo C., Gozal D., Liu R. Depletion of Reduced Glutathione Enhances Motor Neuron Degeneration in Vitro and in Vivo. Neuroscience. 2007;144:991&#x2013;1003. doi: 10.1016/j.neuroscience.2006.09.064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2006.09.064</ArticleId><ArticleId IdType="pmc">PMC1944995</ArticleId><ArticleId IdType="pubmed">17150307</ArticleId></ArticleIdList></Reference><Reference><Citation>Moujalled D., Grubman A., Acevedo K., Yang S., Ke Y.D., Moujalled D.M., Duncan C., Caragounis A., Perera N.D., Turner B.J., et al. TDP-43 Mutations Causing Amyotrophic Lateral Sclerosis Are Associated with Altered Expression of RNA-Binding Protein HnRNP K and Affect the Nrf2 Antioxidant Pathway. Hum. Mol. Genet. 2017;26:1732&#x2013;1746. doi: 10.1093/hmg/ddx093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx093</ArticleId><ArticleId IdType="pubmed">28334913</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y.P., Che F.Y., Su Q.P., Lu Y.C., You C.P., Huang L.M., Wang S.G., Wang L., Yu J.X. Effects of Mutant TDP-43 on the Nrf2/ARE Pathway and Protein Expression of MafK and JDP2 in NSC-34 Cells. Genet. Mol. Res. 2017;16:gmr16029638. doi: 10.4238/gmr16029638.</Citation><ArticleIdList><ArticleId IdType="doi">10.4238/gmr16029638</ArticleId><ArticleId IdType="pubmed">28510254</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Guo W., Mitra J., Hegde P.M., Vandoorne T., Eckelmann B.J., Mitra S., Tomkinson A.E., Van Den Bosch L., Hegde M.L. Mutant FUS Causes DNA Ligation Defects to Inhibit Oxidative Damage Repair in Amyotrophic Lateral Sclerosis. Nat. Commun. 2018;9:3683. doi: 10.1038/s41467-018-06111-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-06111-6</ArticleId><ArticleId IdType="pmc">PMC6134028</ArticleId><ArticleId IdType="pubmed">30206235</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall K.D., Heymsfield S.B., Kemnitz J.W., Klein S., Schoeller D.A., Speakman J.R. Energy Balance and Its Components: Implications for Body Weight Regulation123. Am. J. Clin. Nutr. 2012;95:989&#x2013;994. doi: 10.3945/ajcn.112.036350.</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/ajcn.112.036350</ArticleId><ArticleId IdType="pmc">PMC3302369</ArticleId><ArticleId IdType="pubmed">22434603</ArticleId></ArticleIdList></Reference><Reference><Citation>Cykowski M.D., Takei H., Schulz P.E., Appel S.H., Powell S.Z. TDP-43 Pathology in the Basal Forebrain and Hypothalamus of Patients with Amyotrophic Lateral Sclerosis. Acta Neuropathol. Commun. 2014;2:171. doi: 10.1186/s40478-014-0171-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-014-0171-1</ArticleId><ArticleId IdType="pmc">PMC4297460</ArticleId><ArticleId IdType="pubmed">25539830</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabery S., Ahmed R.M., Caga J., Kiernan M.C., Halliday G.M., Peters&#xe9;n &#xc5;. Loss of the Metabolism and Sleep Regulating Neuronal Populations Expressing Orexin and Oxytocin in the Hypothalamus in Amyotrophic Lateral Sclerosis. Neuropathol. Appl. Neurobiol. 2021;47:979&#x2013;989. doi: 10.1111/nan.12709.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12709</ArticleId><ArticleId IdType="pubmed">33755993</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews J.A., Jackson C.E., Heiman-Patterson T.D., Bettica P., Brooks B.R., Pioro E.P. Real-World Evidence of Riluzole Effectiveness in Treating Amyotrophic Lateral Sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2020;21:509&#x2013;518. doi: 10.1080/21678421.2020.1771734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1771734</ArticleId><ArticleId IdType="pubmed">32573277</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada M., Yamashita S., Ueyama H., Ishizaki M., Maeda Y., Ando Y. Long-Term Effects of Edaravone on Survival of Patients with Amyotrophic Lateral Sclerosis. eNeurologicalSci. 2018;11:11&#x2013;14. doi: 10.1016/j.ensci.2018.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ensci.2018.05.001</ArticleId><ArticleId IdType="pmc">PMC6006910</ArticleId><ArticleId IdType="pubmed">29928711</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S., Hendrix S., Dickson S.P., Knowlton N., Berry J.D., Elliott M.A., Maiser S., Karam C., Caress J.B., Owegi M.A., et al. Effect of Sodium Phenylbutyrate/Taurursodiol on Tracheostomy/Ventilation-Free Survival and Hospitalisation in Amyotrophic Lateral Sclerosis: Long-Term Results from the CENTAUR Trial. J. Neurol. Neurosurg. Psychiatry. 2022;93:871&#x2013;875. doi: 10.1136/jnnp-2022-329024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2022-329024</ArticleId><ArticleId IdType="pmc">PMC9304116</ArticleId><ArticleId IdType="pubmed">35577511</ArticleId></ArticleIdList></Reference><Reference><Citation>Office of the Commissioner FDA Approves New Treatment Option for Patients with ALS.  [(accessed on 24 November 2022)]; Available online:  https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-option-patients-als.</Citation></Reference><Reference><Citation>Zhao Z., Lange D.J., Voustianiouk A., MacGrogan D., Ho L., Suh J., Humala N., Thiyagarajan M., Wang J., Pasinetti G.M. A Ketogenic Diet as a Potential Novel Therapeutic Intervention in Amyotrophic Lateral Sclerosis. BMC Neurosci. 2006;7:29. doi: 10.1186/1471-2202-7-29.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2202-7-29</ArticleId><ArticleId IdType="pmc">PMC1488864</ArticleId><ArticleId IdType="pubmed">16584562</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z., Sui Y., Gao W., Cai B., Fan D. Effects of Diet on Adenosine Monophosphate-Activated Protein Kinase Activity and Disease Progression in an Amyotrophic Lateral Sclerosis Model. J. Int. Med. Res. 2015;43:67&#x2013;79. doi: 10.1177/0300060514554725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0300060514554725</ArticleId><ArticleId IdType="pubmed">25534414</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W., Varghese M., Vempati P., Dzhun A., Cheng A., Wang J., Lange D., Bilski A., Faravelli I., Pasinetti G.M. Caprylic Triglyceride as a Novel Therapeutic Approach to Effectively Improve the Performance and Attenuate the Symptoms Due to the Motor Neuron Loss in ALS Disease. PLoS ONE. 2012;7:e49191. doi: 10.1371/journal.pone.0049191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0049191</ArticleId><ArticleId IdType="pmc">PMC3492315</ArticleId><ArticleId IdType="pubmed">23145119</ArticleId></ArticleIdList></Reference><Reference><Citation>Coughlan K.S., Halang L., Woods I., Prehn J.H.M. A High-Fat Jelly Diet Restores Bioenergetic Balance and Extends Lifespan in the Presence of Motor Dysfunction and Lumbar Spinal Cord Motor Neuron Loss in TDP-43A315T Mutant C57BL6/J Mice. Dis. Model. Mech. 2016;9:1029&#x2013;1037. doi: 10.1242/dmm.024786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.024786</ArticleId><ArticleId IdType="pmc">PMC5047697</ArticleId><ArticleId IdType="pubmed">27491077</ArticleId></ArticleIdList></Reference><Reference><Citation>Wills A.-M., Hubbard J., Macklin E.A., Glass J., Tandan R., Simpson E.P., Brooks B., Gelinas D., Mitsumoto H., Mozaffar T., et al. Hypercaloric Enteral Nutrition in Amyotrophic Lateral Sclerosis: A Randomized Double-Blind Placebo-Controlled Trial. Lancet. 2014;383:2065&#x2013;2072. doi: 10.1016/S0140-6736(14)60222-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)60222-1</ArticleId><ArticleId IdType="pmc">PMC4176708</ArticleId><ArticleId IdType="pubmed">24582471</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst J., Cypionka J., Ludolph A.C. High-Caloric Food Supplements in the Treatment of Amyotrophic Lateral Sclerosis: A Prospective Interventional Study. Amyotroph. Lateral Scler. Front. Degener. 2013;14:533&#x2013;536. doi: 10.3109/21678421.2013.823999.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.823999</ArticleId><ArticleId IdType="pubmed">23944684</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A.C., Dorst J., Dreyhaupt J., Weishaupt J.H., Kassubek J., Weiland U., Meyer T., Petri S., Hermann A., Emmer A., et al. Effect of High-Caloric Nutrition on Survival in Amyotrophic Lateral Sclerosis. Ann. Neurol. 2020;87:206&#x2013;216. doi: 10.1002/ana.25661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25661</ArticleId><ArticleId IdType="pubmed">31849093</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva L.B.D.C., Mour&#xe3;o L.F., Silva A.A., Lima N.M.F.V., Almeida S.R., Franca M.C., Nucci A., Amaya-Farf&#xe1;n J. Effect of Nutritional Supplementation with Milk Whey Proteins in Amyotrophic Lateral Sclerosis Patients. Arq. Neuro-Psiquiatr. 2010;68:263&#x2013;268. doi: 10.1590/S0004-282X2010000200021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S0004-282X2010000200021</ArticleId><ArticleId IdType="pubmed">20464297</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto K., Kihira T., Kondo T., Kobashi G., Washio M., Sasaki S., Yokoyama T., Miyake Y., Sakamoto N., Inaba Y., et al. Nutritional Status and Risk of Amyotrophic Lateral Sclerosis in Japan. Amyotroph. Lateral Scler. 2007;8:300&#x2013;304. doi: 10.1080/17482960701472249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960701472249</ArticleId><ArticleId IdType="pubmed">17852010</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragagnin A.M.G., Shadfar S., Vidal M., Jamali M.S., Atkin J.D. Motor Neuron Susceptibility in ALS/FTD. Front. Neurosci. 2019;13:532. doi: 10.3389/fnins.2019.00532.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00532</ArticleId><ArticleId IdType="pmc">PMC6610326</ArticleId><ArticleId IdType="pubmed">31316328</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalancette-Hebert M., Sharma A., Lyashchenko A.K., Shneider N.A. Gamma Motor Neurons Survive and Exacerbate Alpha Motor Neuron Degeneration in ALS. Proc. Natl. Acad. Sci. USA. 2016;113:E8316&#x2013;E8325. doi: 10.1073/pnas.1605210113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1605210113</ArticleId><ArticleId IdType="pmc">PMC5187676</ArticleId><ArticleId IdType="pubmed">27930290</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>